Ctnb1 as a marker for endometrial cancer
OwnerElena MARTINEZ GARCÍA, Eva COLÁS ORTEGA +5inventors
InventorsElena MARTINEZ GARCÍA, Eva COLÁS ORTEGA, Antonio GIL MORENO, Jaume REVENTÓS PUIGJANER, Bruno DOMON, Antoine LESUR, Irene CAMPOY MONCAYO
Life of this patent
Estimating the term…
Abstract
Present invention provides a method for diagnosing and prognosing endometrial cancer in easy-to-access isolated samples by detecting the level of expression of one or more proteins. In particular from uterine fluid samples. The invention also provides kits comprising means for detecting said proteins for use in the diagnosis and prognosis of the disease.
Claims23
A method of diagnosing and treating a subject suspected of having endometrial cancer, the method comprising:
- (a) obtaining a uterine fluid sample from the female genital tract of the subject;
- (b) determining the level of expression of AGRIN in the uterine fluid sample from the female genital tract;
- and
- (c) initiating a medical regimen to treat the subject for endometrial carcinoma if the level of expression of AGRIN is higher than a reference control level.
-9. (canceled)
14-19. (canceled)
A kit comprising a solid support and means for detecting the level of expression of AGRIN and, optionally, means for detecting the level of expression of the proteins of at least one set of proteins selected from the group consisting of AGRIN, CD81, TERA;
- AGRIN, CD59, MVP;
- AGR2, AGRIN, CD81;
- AGRIN, CD166, MVP;
- AGRIN, CD81;
- AGRIN, CD166;
- AGRIN, CD59;
- AGRIN, MMP9;
- AGRIN, BCAM;
- AGRIN, MMP9, PODXL;
- AGRIN, MMP9;
- and AGRIN, MMP9, PIGR.
21-22. (canceled)
Dependencies are inferred from the claim text.